

LIBERIA Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia			
2. Grant number(s): 19-LBR-25c-X; 15-LBR-08h-Y			
3. Date of Decision Letter: 5 March 2019			
4. Date of the Partnership Framework Agreement: 19 August 2013			
5. Programme title: NVS, IPV routine			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 10 doses per vial, LIQUID			
8. Programme duration²: 2015 - 2019			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement, if applicable) <i>Please note that endorsed or approved amounts for 2020 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2018	2019	Total ³
Routine Programme (US\$)	272,639 ⁴	324,000	596,639
10. Vaccine introduction grant: US\$ 125,000 disbursed on 25 July 2014			
11. Product switch grant: Not applicable			
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁵			
Number of vaccines to be purchased with Gavi funds	2015-2018	2019	
IPV Routine Programme (doses)		141,300	
Annual Amounts (US\$)	272,639	324,000	
13. Procurement agency: UNICEF			
14. Self-procurement: N/A			

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2019.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

<p>15. Co-financing obligations: Not applicable</p> <p>Gavi's usual co-financing requirements do not apply to IPV. However, Liberia is encouraged to contribute to vaccine and/or supply costs for IPV.</p>							
<p>16. Operational support for catch-up campaigns: Not applicable</p>							
<p>17. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td> <p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p> </td> <td> <p>To be agreed with Secretariat</p> </td> </tr> </tbody> </table>			Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>	<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>
	Due dates						
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>						
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>						
<p>18. Financial clarifications: N/A</p>							
<p>19. Other conditions:</p> <p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p> <p>If Liberia envisages a switch in product presentation, it is encouraged to incorporate elements for both IPV presentations in your initial introduction preparations, in order to minimise the need for later interventions and facilitate the switch. In those circumstances, in principle, no product switch grant will be provided to Liberia.</p>							

On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes
 5 March 2019

LIBERIA Support for Pneumococcal Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia				
2. Grant number: 1820-LBR-12d-X; 13-LBR-08c-Y; 18-LBR-25a-Y				
3. Date of Decision Letter: 5 March 2019				
4. Date of the Partnership Framework Agreement: 19 August 2013				
5. Programme title: New Vaccine Support (NVS), Pneumococcal Routine				
6. Vaccine type: Pneumococcal				
7. Requested product presentation and formulation of vaccine: Pneumococcal (PCV13), 4 doses per vial , LIQUID				
8. Programme duration¹: 2013 -2020				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2013-2018	2019	2020	Total ²
Programme Budget (US\$)	8,675,210 ³	1,435,000	1,586,500	11,696,710
10. Vaccine introduction grant (in US\$): US\$ 155,000 disbursed on 18 November 2013				
11. Product switch grant: US\$ 46,007 disbursed on 17 August 2018				
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2013-2018			2019
Number of Pneumococcal vaccines doses				426,600
Annual Amounts (US\$)	8,675,210 ⁵			1,435,000
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
14. Self-procurement: N/A				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>15. Co-financing obligations: Reference code: 1820-LBR-12d-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>								
Type of supplies to be purchased with Country funds in each year	2019	2020						
Number of vaccine doses	30,800	39,200						
Value of vaccine doses (US\$)	90,372	115,187						
Total co-financing payments (US\$) (including freight)	91,500	117,000						
<p>16. Operational support for campaigns: Not applicable</p>								
<p>17. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td> <p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p> </td> <td> <p>To be agreed with Secretariat</p> </td> </tr> </tbody> </table>				Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>	<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>
	Due dates							
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>							
<p>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</p>	<p>To be agreed with Secretariat</p>							
<p>18. Financial clarifications: N/A</p>								
<p>19. Other conditions: N/A</p>								

On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes
 5 March 2019

LIBERIA Support for Pentavalent Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia				
2. Grant number: 1820-LBR-04c-X; 07-LBR-08b-Y; 18-LBR-04g-Y				
3. Date of Decision Letter: 5 March 2019				
4. Date of the Partnership Framework Agreement: 19 August 2013				
5. Programme title: New Vaccine Support (NVS), Pentavalent Routine				
6. Vaccine type: Pentavalent				
7. Requested product presentation and formulation of vaccine: DTP-HepB-Hib, 10 doses per vial, LIQUID				
8. Programme duration¹: 2008 -2020				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2008-2018	2019	2020	Total ²
Programme Budget (US\$)	10,996,609 ³	332,000	349,000	11,677,609
10. Vaccine introduction grant (in US\$): US\$ 100,000 disbursed on 27 July 2007				
11. Product switch grant: US\$ 35,680 disbursed on 31 August 2018				
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2008-2018	2019		
Number of Pentavalent vaccines doses		466,500		
Annual Amounts (US\$)	10,996,609 ⁵	332,000		
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
14. Self-procurement: N/A				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>15. Co-financing obligations: Reference code: 1820-LBR-04c-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>								
Type of supplies to be purchased with Country funds in each year	2019	2020						
Number of vaccine doses	182,500	192,000						
Value of vaccine doses (US\$)	125,906	132,405						
Total co-financing payments (US\$) (including freight)	130,000	136,500						
<p>16. Operational support for campaigns: Not applicable</p>								
<p>17. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>				Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
	Due dates							
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>							
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat							
<p>18. Financial clarifications: N/A</p>								
<p>19. Other conditions: N/A</p>								

On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes
 5 March 2019

LIBERIA

Support for Yellow Fever Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia				
2. Grant number: 1720-LBR-06b-X				
3. Date of Decision Letter: 5 March 2019				
4. Date of the Partnership Framework Agreement: 19 August 2013				
5. Programme title: NVS, Yellow Fever Routine				
6. Vaccine type: Yellow Fever				
7. Requested product presentation and formulation of vaccine: Yellow Fever, 10 doses per vial, LYOPHILISED				
8. Programme duration¹: 2001 -2020				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2001-2018	2019	2020	Total ²
Programme Budget (US\$)	2,248,056 ³	253,500	263,000	2,764,556
10. Vaccine introduction grant (in US\$): N/A				
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable): ⁴				
Type of supplies to be purchased with Gavi funds in each year	2001-2018	2019		
Number of Yellow Fever vaccines doses		207,500		
Annual Amounts (US\$)	2,248,056 ⁵	253,500		
12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
13. Self-procurement: N/A				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

14. Co-financing obligations: Reference code: 1720-LBR-06b-X-C

According to the co-financing policy, the Country falls within the group Initial self-financing.

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019	2020
Number of vaccine doses	40,700	41,400
Value of vaccine doses (US\$)	47,555	48,818
Total co-financing payments (US\$) (including freight)	50,000	51,000

15. Operational support for campaigns: N/A

16. Additional reporting requirements:

	Due dates
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat

17. Financial clarifications: N/A

18. Other conditions: There is currently a global shortage in the supply of yellow fever vaccines. The number of doses and presentation are subject to availability. Gavi will inform the Government as soon as possible of any changes in doses and/or presentation from what has been communicated to the Country.

On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes
 5 March 2019

LIBERIA Support for Rotavirus Vaccine

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Liberia				
2. Grant number: 1720-LBR-13b-X; 15-LBR-08b-Y				
3. Date of Decision Letter: 5 March 2019				
4. Date of the Partnership Framework Agreement: 19 August 2013				
5. Programme title: New Vaccine Support (NVS), Rotavirus Routine				
6. Vaccine type: Rotavirus				
7. Requested product presentation and formulation of vaccine: Rotavirus, 2 doses schedule				
8. Programme duration¹: 2015 -2020				
9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)				
	2015-2018	2019	2020	Total ²
Programme Budget (US\$)	2,111,389 ³	607,000	759,500	3,477,889
10. Vaccine introduction grant (in US\$): US\$ 139,000 disbursed on 20 November 2015				
11. Product switch grant: Not applicable				
12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable) ⁴				
Type of supplies to be purchased with Gavi funds in each year	2015-2018	2019		
Number of Rotavirus vaccines doses		261,000		
Annual Amounts (US\$)	2,111,389 ⁵	607,000		
13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.				
14. Self-procurement: N/A				

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁴ This is the amount that Gavi has approved.

⁵ This is the consolidated amount for all previously approved years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

<p>15. Co-financing obligations: Reference code: 1720-LBR-13b-X-C</p> <p>According to the co-financing policy, the Country falls within the group Initial self-financing.</p> <p>The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>								
Type of supplies to be purchased with Country funds in each year	2019	2020						
Number of vaccine doses	25,500	31,500						
Value of vaccine doses (US\$)	55,678	69,671						
Total co-financing payments (US\$) (including freight)	57,500	72,000						
<p>16. Operational support for campaigns: Not applicable</p>								
<p>17. Additional reporting requirements:</p> <table border="1"> <thead> <tr> <th></th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td> <p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. </td> <td> <p>31 March 2019</p> <p>15 May 2019</p> </td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>				Due dates	<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
	Due dates							
<p>To prepare for the annual procurement of vaccines, Country shall submit the following information each year:</p> <ul style="list-style-type: none"> vaccine stock levels including buffer stock, by end of March; number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation. 	<p>31 March 2019</p> <p>15 May 2019</p>							
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat							
<p>18. Financial clarifications: N/A</p>								
<p>19. Other conditions: N/A</p>								

On behalf of Gavi



Hind Khatib-Othman
 Managing Director, Country Programmes
 5 March 2019